REQUEST FOR PROPOSALS: Accelerating DRUG DISCOVERY for Frontotemporal Degeneration

Funding Agency:
Alzheimer’s Drug Discovery Foundation

There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP).


  • Letter of Intent: May 19th, 2023

  • Invited Full Proposal: July 28th, 2023

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians in the U.S. and worldwide working in:

  • Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
  • Biotechnology companies that demonstrate a clear need for nonprofit funding. Existing companies and new spinouts are both eligible.

Amount Description

$150,000-$200,000 based on stage and scope of research. Slightly higher budgets can be considered. Please contact us for review and approval.



Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 19, 2023